Back to results
US 2022/0177600 A1Published application
Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
AssigneeJanux Therapeutics, Inc.
InventorsDavid CAMPBELL, Thomas R. DiRaimondo
Life of this patent
Estimating the term…
Abstract
Provided herein are multispecific antibodies that selectively bind to PSMA and effector cell antigens such as CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
Claims30
A polypeptide or polypeptide complex according to Formula I:
- A2-A1-L1-P1—H1 (Formula I)
- wherein:
- A1 comprises a first antigen recognizing molecule that binds to an effector cell antigen;
- P1 comprises a peptide that binds to A1;
- L1 comprises a linking moiety that connects A1 to P1 and is a substrate for a tumor specific protease;
- H1 comprises a half-life extending molecule;
- and
- A2 comprises a second antigen recognizing molecule that binds to prostate-specific membrane antigen (PSMA).
5 more elements
Dependencies are inferred from the claim text.